First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain

对健康和阿尔茨海默病大脑中星形细胞谷氨酸转运蛋白 (EAAT2) PET 示踪剂的首次人体评估

基本信息

  • 批准号:
    10683344
  • 负责人:
  • 金额:
    $ 81.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-15 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Alzheimer’s disease (AD) and related dementias represent a growing public health concern with tremendous impact on patients and their families. Efforts to treat AD effectively are partially confounded by different hypotheses regarding its initiation and progression. The varying hypotheses are reflected in the range of highly informative imaging methods used to study AD and its progression, such as positron emission tomography (PET) targeted to specific cerebral proteins. In this project we will develop a novel [18F]-labeled PET imaging tracer, RP-115, to evaluate changes in astrocytes in healthy versus cognitively impaired AD patients by quantitative PET imaging of the excitatory amino acid transporter 2 (EAAT2) that is primarily localized on astrocytes and is significantly down-regulated in select cerebral regions of AD brain. The project hypothesis is that regional cerebral decreases of RP-115 tracer binding to astrocyte EAAT2 detected by PET imaging in live human brain can be used as an early and sensitive measure of AD onset and progression. The first-in-human project objective is composed with two translational development goals: 1) to establish RP-115 tracer human safety, and 2) to utilize the tracer to assess regional cerebral EAAT2 tracer binding differences in healthy vs. Ab-, pTau- and cognitively-defined AD patients; and compare the EAAT2 AD data to existing AD FDG and MAO-B astrocytic-related PET profiles. We will test the hypothesis and satisfy the translational project objective by accomplishing three Specific Aims. Aim 1: Establish RP-115 safety in the clinic with male and female PET imaging. Aim 2: Acquire RP-115 EAAT2 imaging data in well-defined male and female healthy control and AD patient cohorts. Aim 3: Analyze the PET imaging data.
项目摘要 阿尔茨海默病(AD)和相关痴呆代表了日益增长的公共卫生问题, 对患者及其家属的影响。有效治疗AD的努力部分受到不同的干扰。 关于其启动和进展的假设。不同的假设反映在高度 用于研究AD及其进展的信息性成像方法,如正电子发射断层扫描 (PET)针对特定的大脑蛋白质。在这个项目中,我们将开发一种新的[18F]标记的PET成像 示踪剂,RP-115,以评估健康与认知受损AD患者中星形胶质细胞的变化, 兴奋性氨基酸转运蛋白2(EAAT 2)的定量PET成像,主要定位于 在AD脑的选择脑区域中显著下调。 该项目的假设是,RP-115示踪剂与星形胶质细胞EAAT 2结合的局部脑减少 在活体人脑中通过PET成像检测到的AD可以用作AD发作的早期和灵敏的测量, 进展第一个人类项目目标由两个转化发展目标组成:1) 建立RP-115示踪剂的人体安全性,2)利用示踪剂评估局部脑EAAT 2示踪剂 健康与Ab-、pTau-和认知定义的AD患者的结合差异;并比较EAAT 2 AD 现有AD FDG和MAO-B星形胶质细胞相关PET图谱的数据。我们将测试假设并满足 通过实现三个具体目标来实现项目目标。目的1:确定RP-115在 男性和女性的PET成像。目的2:在轮廓分明的男性中采集RP-115 EAAT 2成像数据 以及女性健康对照和AD患者队列。目的3:分析PET成像数据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN M GERDES其他文献

JOHN M GERDES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN M GERDES', 18)}}的其他基金

First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain
对健康和阿尔茨海默病大脑中星形细胞谷氨酸转运蛋白 (EAAT2) PET 示踪剂的首次人体评估
  • 批准号:
    10539917
  • 财政年份:
    2022
  • 资助金额:
    $ 81.68万
  • 项目类别:
Nonhuman Primate CNS Assessments of 18F-Insulin After IntranasalAdministration
鼻内给药后 18F-胰岛素的非人灵长类 CNS 评估
  • 批准号:
    9762775
  • 财政年份:
    2017
  • 资助金额:
    $ 81.68万
  • 项目类别:
Nonhuman Primate CNS Assessments of 18F-Insulin After Intranasal Administration
鼻内给药后 18F-胰岛素的非人灵长类 CNS 评估
  • 批准号:
    9226873
  • 财政年份:
    2017
  • 资助金额:
    $ 81.68万
  • 项目类别:
Molecular Imaging of Chemical Threats and Countermeasures
化学威胁的分子成像及对策
  • 批准号:
    9330941
  • 财政年份:
    2015
  • 资助金额:
    $ 81.68万
  • 项目类别:
Molecular Imaging of Chemical Threats and Countermeasures
化学威胁的分子成像及对策
  • 批准号:
    9113105
  • 财政年份:
    2015
  • 资助金额:
    $ 81.68万
  • 项目类别:
Molecular Imaging of Chemical Threats and Countermeasures
化学威胁的分子成像及对策
  • 批准号:
    9760008
  • 财政年份:
    2015
  • 资助金额:
    $ 81.68万
  • 项目类别:
In Vivo Pharmacokinetic and Pharmacodynamic Dispositions of Positron Radiolabeled
正电子放射性标记的体内药代动力学和药效学分布
  • 批准号:
    8020760
  • 财政年份:
    2010
  • 资助金额:
    $ 81.68万
  • 项目类别:
In Vivo Pharmacokinetic and Pharmacodynamic Dispositions of Positron Radiolabeled
正电子放射性标记的体内药代动力学和药效学分布
  • 批准号:
    8152267
  • 财政年份:
    2010
  • 资助金额:
    $ 81.68万
  • 项目类别:
PET Imaging Tracers to Quantify Norepinephrine Transporter in the Brain
PET 成像示踪剂可量化大脑中的去甲肾上腺素转运蛋白
  • 批准号:
    7899835
  • 财政年份:
    2009
  • 资助金额:
    $ 81.68万
  • 项目类别:
MT COBRE: MAPPING SEROTONIN TRANSPORTER BINDING DOMAINS
MT COBRE:绘制血清素转运蛋白结合域图
  • 批准号:
    7720402
  • 财政年份:
    2008
  • 资助金额:
    $ 81.68万
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Collaborative R&D
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
  • 批准号:
    23K20355
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
  • 批准号:
    23K24782
  • 财政年份:
    2024
  • 资助金额:
    $ 81.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了